Is the Instantaneous Wave-Free Ratio Equivalent to Fractional Flow Reserve?
We read the paper by Sen et al. (1) with great interest; the study was designed to explore whether the instantaneous wave-free ratio (iFR) was an adenosine-free alternative to fractional flow reserve (FFR) for the assessment of coronary stenosis. Hyperemic stenosis resistance (HSR) was used as a reference standard to determine when iFR and FFR disagreed as to which index was most representative of the hemodynamic significance of the stenosis. It was concluded that iFR and FFR had equivalent agreement with classification of coronary stenosis severity by HSR, and the administration of adenosine did not improve diagnostic categorization. However, we have several concerns regarding the data the study presented.
First, the well-designed study only investigated 51 vessels, which significantly reduces the reliability of the result. We noticed that in the 4 lesions of 2 groups (iFR [À] and FFR(þ); iFR(þ) and FFR [À] ), in which there was disagreement, HSR agreed with FFR in 1 case (50%) and with iFR in the other case (50%) for each group, respectively (1) . Based on these data, how could we trust that iFR and FFR were equally representative of the hemodynamic significance of the stenosis rather than an element of serendipity? It was not convincible that "the proportion (7.7%) is consistent with clinical populations, the ADVISE Registry (6%), and South Korean Study (6%), suggesting that the study findings are consistent with other, larger datasets" (1) .
Second, we noted that "using the established ischemic cut-off point of >0.8 mm Hg/cm$s for HSR (2) ," a 0.75 cutoff point for FFR was found to have an optimal diagnostic efficiency of 0.96 (1) . The cutoff for HSR was certainly key to the study, which was used to determine the cutoff of iFR and FFR and dominated the disagreement between them. However, the problem is that there is no evidence of the socalled "established ischemic cut-off point of >0.8 mm Hg/cm$s for HSR" in the study by Christou et al (2) . What is wrong with that? Could we just explain it as a mistake? Because we did find a paper (3) to validate a cutoff of >0.8 mm Hg/cm$s for HSR, which was also cited in the study. If so, we have to know if this was the only paper (3) to date to determine such a cutoff of HSR without reproducibility. Furthermore, possible influences of hemodynamic alterations (heart rate, aortic pressure, contractility) on HSR have not been investigated (3) .
In summary, it was of great significance for the study to clarify whether iFR was an adenosine-free alternative to FFR, especially when the VERIFY (Verification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in Everyday Practice) study (4) indicated that iFR correlates weakly with FFR and was not independent of hyperemia. However, maybe we should not take the urgency, but the large-sized algorithm, to clarify the issue. Moreover, it might be advisable to find a well-validated, pressure-and-flow index as a reference standard. 
Reply
Is (2) trials. This detailed analysis is sorely needed in our community. In suggesting that "the VERIFY study indicated that instant wave-free ratio (iFR) correlates weakly with fractional flow reserve (FFR) and was not independent of hyperemia," Fan and Xu should be aware of 2 key points.
First, there are major differences in the way iFR was calculated in VERIFY compared with our work (3). Some of these differences are graphically depicted in Figure 1 of the VERIFY paper (2), clearly demonstrating that Berry et al. failed to identify "diastole." Instead, they actually included a portion of systole in their "diastolic period." As readers are aware, resistance during systole is neither constant nor minimized; such basic methodological errors may explain why iFR-FFR classification match was significantly lower in VERIFY than in any other reported comparative study (Fig. 1) . When the analysis was performed by an independent neutral third party using the validated iFR algorithm in RESOLVE (4), the claims of the VERIFY investigators could not be substantiated (with 80% iFR-FFR agreement rather than the 51% to 60% reported by Berry et al. [2] ). An additional reason for the poor iFR-FFR match in VERIFY could be due to the variable iFR cutpoint used within the same study. For example, an iFR cutpoint of 0.83 was used in the results section of VERIFY, whereas, confusingly, in the abstract, they report data for an iFR cutpoint of 0.80. In reality, Berry et al. (2) knew the optimal receiver-operating characteristic derived cutpoint for VERIFY-iFR in their dataset was neither. Playing with numbers in this manner can only depress any possible link between iFR and FFR. We encourage the readership to check whether the early FFR work identified an optimal cutpoint and then in the same dataset deliberately used a suboptimal one.
Second, demonstrating that iFR was independent of hyperemia was never an objective or a claim of our work, but instead, we simply aimed to achieve stenosis classification similar to that obtained with FFR but without (or independent of) the need of adenosine administration. However, it is important to note that CLARIFY (1) demonstrated that adding adenosine infusion to the iFR calculation did not improve diagnostic accuracy, rendering the key finding of VERIFY clinically irrelevant.
Regarding the validation of hyperemic stenosis resistance (HSR), we believe that the publications by Meuwissen et al. (5) provide sufficient evidence for its use as a valid reference standard in our study. HSR has the advantage of having a better discriminant value than FFR because it really does measure flow, which is the crucial feature for the thirsting myocardium. Among studies of this kind, which used flow and pressure, CLARIFY is the second-largest ever conducted, and the first to publish. The vintage physiological studies of FFR were smaller, and as underlined by Fan and Xu, reported diagnostic accuracies that were later overturned by larger studies from independent investigators (6) (as is the also the case for VERIFY).
Although CLARIFY demonstrated iFR to be noninferior to FFR, we are honored to report that the world's largest comparison of iFR and FFR against HSR has been performed by a team including the FFR pioneers, Pijls and Gould (7). This independent analysis of 120 stenoses suggests iFR may be superior to FFR. Is this more serendipity? *Sayan Sen We read with great interest the article by Larsen et al. (1) examining the safety of dabigatran, especially with regard to myocardial infarction (MI) and gastrointestinal bleeding using Danish national databases. They report a remarkable, highly significant 60% to 70% risk reduction in MIs with dabigatran as compared with warfarin (p < 0.0001). Similarly, they report a 40% reduction in incident gastrointestinal bleeding with 110 mg dabigatran twice daily compared with warfarin, which was again statistically significant. (2) (3) (4) (5) (6) . Combined analysis of all these trials shows a 48% increase in MIs with dabigatran as compared to controls (p ¼ 0.005) (Fig. 1) . Removal of any single study, including the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial (3) that generated the hypothesis that dabigatran increases risk of MI, does not change the statistically significant excess in MIs. On the other hand, regarding the gastrointestinal bleeding risk, the RE-LY trial reported this event in 10% of patients receiving dabigatran 110 mg twice daily and in 7.5% of patients receiving warfarin (p < 0.00001 for dabigatran vs. warfarin) (2) . In this trial the excess in gastrointestinal bleeding events was even more pronounced for dabigatran 150 mg twice daily compared with warfarin. The RE-COVER (Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism) trial also showed an excess in gastrointestinal bleeding with dabigatran as compared with warfarin (4.2% vs. 2.8%) (5) . Therefore, the results of both the Larsen et al. (1) current observational study and the randomized controlled clinical trials show significant differences in MI and gastrointestinal bleeding rates with dabigatran versus warfarin, but in completely opposite directions. We think that the imperfect nature of observational studies mostly stemming from residual confounding despite propensity matching may explain the discrepancy between the current observational study and previous randomized trials. Can the authors provide their perspective on the risk of residual confounding in their analysis? Figure 1 Forest 
